Top segments and regional performance

Last year, the company generated 164.07 M USD, the most of which — 164.07 M USD — came from its top-performing segment, Autologous Tumor Infiltrating Lymphocyte Cell Therapies, compared to 1.19 M USD the previous year. The greatest contribution came from United States, which accounted for 161.04 M USD last year, with 1.19 M USD the year before.